Christopher Garabedian

2014

In 2014, Christopher Garabedian earned a total compensation of $5M as Former President and Chief Executive Officer at Sarepta Therapeutics, a 48% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$289,536
Option Awards$3,990,798
Salary$603,200
Other$119,492
Total$5,003,026

Garabedian received $4M in option awards, accounting for 80% of the total pay in 2014.

Garabedian also received $289.5K in non-equity incentive plan, $603.2K in salary and $119.5K in other compensation.

Rankings

In 2014, Christopher Garabedian's compensation ranked 1,552nd out of 13,032 executives tracked by ExecPay. In other words, Garabedian earned more than 88.1% of executives.

ClassificationRankingPercentile
All
1,552
out of 13,032
88th
Division
Manufacturing
556
out of 4,965
89th
Major group
Chemicals And Allied Products
176
out of 1,690
90th
Industry group
Drugs
137
out of 1,369
90th
Industry
Pharmaceutical Preparations
117
out of 1,042
89th
Source: SEC filing on May 31, 2016.

Garabedian's colleagues

We found five more compensation records of executives who worked with Christopher Garabedian at Sarepta Therapeutics in 2014.

2014

Arthur Krieg

Sarepta Therapeutics

Chief Scientific Officer

2014

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2014

Edward Kaye

Sarepta Therapeutics

Chief Executive Officer

2014

David Howton

Sarepta Therapeutics

General Counsel

2014

Jayant Aphale

Sarepta Therapeutics

Senior Vice President, Technical Operations

In-depth

You may also like